Beigene, Ltd. (NASDAQ:ONC) Receives $319.00 Average PT from Brokerages

Shares of Beigene, Ltd. (NASDAQ:ONC - Get Free Report) have received an average recommendation of "Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $319.00.

Several equities analysts recently commented on the stock. Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a report on Thursday, March 13th. Wall Street Zen raised shares of Beigene from a "hold" rating to a "buy" rating in a research report on Thursday. JPMorgan Chase & Co. boosted their price objective on shares of Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a research report on Monday, April 21st. Macquarie boosted their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $207.00 to $320.00 in a research report on Monday, March 3rd.

Beigene Stock Up 1.1%

NASDAQ:ONC traded up $2.67 during mid-day trading on Monday, hitting $241.43. 171,472 shares of the stock traded hands, compared to its average volume of 466,365. The stock has a market cap of $23.91 billion, a PE ratio of -29.30, a price-to-earnings-growth ratio of 7.73 and a beta of 0.35. Beigene has a 52 week low of $141.31 and a 52 week high of $287.88. The stock has a 50 day moving average price of $241.35. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. As a group, research analysts predict that Beigene will post -5.82 EPS for the current year.

Insider Transactions at Beigene

In other Beigene news, Director Bros. Advisors Lp Baker sold 732,827 shares of the company's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the transaction, the director now owns 730,642 shares in the company, valued at approximately $189,966,920. This represents a 50.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Xiaodong Wang sold 8,146 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68. Following the sale, the insider now directly owns 5,240,882 shares in the company, valued at $1,334,223,739.56. This trade represents a 0.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,129,685 shares of company stock valued at $290,450,134. Company insiders own 6.62% of the company's stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.